Silvana Novelli
@snovelli.bsky.social
📤 206
📥 295
📝 42
Hematologist.
#Lymphoma
#immunotherapy
#ITP
🏥 Institut Català d’Oncologia- Barcelona. Tap dancer 🎼
What a beautiful work from our colleagues from Navarra!
@unav.edu
#CUN
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality
#MM
ashpublications.org/blood/articl...
loading . . .
Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma
Key Points. Glutamine deprivation in the tumor microenvironment might limit CAR T-cell therapeutic efficacy in cancer patients.ASCT2 overexpression improve
https://ashpublications.org/blood/article/doi/10.1182/blood.2024027496/547364/Reprogramming-glutamine-metabolism-enhances-BCMA?searchresult=1
3 days ago
0
0
0
Improved PFS with Moga-Chop for elderly ATL patients. I wonder how the Moga -Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
loading . . .
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma
Key PointsMoga-CHOP significantly improved 1-year PFS in older patients with aggressive ATL.CCR4 mutations and Moga-associated cAEs were related to better
https://ashpublications.org/blood/article-abstract/146/12/1440/537311/A-phase-2-trial-of-CHOP-with-anti-CCR4-antibody?redirectedFrom=fulltext
3 days ago
0
0
0
🏁Avui
#bcnhop
#dansaurbana
www.barcelona.cat/barcelonacul...
loading . . .
Dansa, resistència i metàfora a l'Hop Festival | Barcelona Cultura
Sandra Egido inaugura el festival amb dues peces que fusionen el breaking i la dansa contemporània en clau crítica i poètic... Fes clic per saber-ne més!
https://www.barcelona.cat/barcelonacultura/ca/recomanem/dansa-resistencia-metafora-hop-festival
5 days ago
0
0
0
reposted by
Silvana Novelli
Kate Sears
10 days ago
🧠 Neurotoxicity in Cancer Therapy New review (Nat Rev Clin Oncol) ✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity ✅ Clinical recognition & biomarkers ✅ Prevention & management strategies 🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
1
4
2
reposted by
Silvana Novelli
Immunity
11 days ago
loading . . .
Touch of youth: Mechanosensing expands stem-like CAR-T cells
In this issue of Immunity, Lv et al. develop a new CAR-T cell culture system that uses integrin mechanical signaling to boost CAR-T proliferation while preserving stemness, pointing out a new direction of CAR-T manufacturing.
http://dlvr.it/TN3dVz
0
2
2
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url:
ashpublications.org/thehematolog...
loading . . .
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V22.5.202557/546918/WU-Hoo-The-Promise-of-Allogeneic-WU-CART-007-in
15 days ago
0
1
1
reposted by
Silvana Novelli
Society of Hematologic Oncology
16 days ago
Addition of lisaftoclax to myeloma regimens improved depth of response
sohoinsider.com/meetings-con...
loading . . .
lisaftoclax boosts response in mm, amyloidosis - SOHO Insider
Phase 1b/2 study shows lisaftoclax with Pd or DRd yields 61.3% ORR in relapsed MM, AL amyloidosis at SOHO 2025
https://sohoinsider.com/meetings-conferences/lisaftoclax-phase-1b-2-multiple-myeloma-amyloidosis/
0
3
2
Devimistat shows potential for a subset of BL patients, efforts should focus on improving initial therapies and exploring novel treatments for these challenging malignancies:
ashpublications.org/bloodadvance...
loading . . .
Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial
Key Points. A targeted approach to block enzymes in the TCA cycle had limited efficacy in the treatment of patients with relapsed Burkitt lymphoma.The uniq
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016168/546236/Novel-Devimistat-Results-in-Complete-Remissions-in
17 days ago
0
0
1
reposted by
Silvana Novelli
Eric Topol
18 days ago
Fraud, using A.I., impersonating medical professionals Front page NY Times
www.nytimes.com/2025/09/05/t...
6
120
53
reposted by
Silvana Novelli
OncLive
19 days ago
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL
@societyofhemonc.bsky.social
@brownmedicine.bsky.social
#SOHO2025
#lymsm
www.onclive.com/view/mosunet...
loading . . .
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL
A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.
https://www.onclive.com/view/mosunetuzumab-plus-polatuzumab-vedotin-triples-median-pfs-in-transplant-ineligible-lbcl
0
0
1
reposted by
Silvana Novelli
Jeffrey Perkel (he/him)
29 days ago
PS: I wrote about marimo in a larger feature on how to pick a programming language
@nature.com
:
www.nature.com/articles/d41...
loading . . .
Which programming language should I use? A guide for early-career researchers
Computer scientists and bioinformaticians address four key questions to help rookie coders to make the right choice.
https://www.nature.com/articles/d41586-025-01241-6
0
2
1
First-ever comparison between haplo-HSCT using modified post-transplantation cyclophosphamide and combined IST+EPAG.
www.astctjournal.org/article/S266...
loading . . .
Comparison of haploidentical-hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide and eltrombopag combined with immunosuppression for the treatment of severe ap...
Severe aplastic anemia (SAA) is a life-threatening disease mainly caused by abnormal immune function in the form of T lymphocyte hyperfunction 1. SAA and very SAA (VSAA) can be treated with human leuk...
https://www.astctjournal.org/article/S2666-6367(25)01331-4/abstract
about 2 months ago
0
2
1
I suppose MRD would help explain why the indirect comparison of Epco vs Odro shows a benefit for Epco, despite having a lower CRR (but higher ORR)
ashpublications.org/bloodadvance...
loading . . .
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Key PointsIn this indirect comparison, epcoritamab significantly improved response and survival vs CIT in patients with relapsed or refractory third-line o
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015274/537623/Indirect-comparison-of-epcoritamab-vs
about 2 months ago
0
0
1
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis, regardless of MGUS status, amazing work!:
ashpublications.org/bloodadvance...
loading . . .
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis
TO THE EDITOR:
https://ashpublications.org/bloodadvances/article/9/15/3766/537151/Dysregulated-immune-proteins-in-plasma-in-the-UK
about 2 months ago
0
1
3
reposted by
Silvana Novelli
Trends in Immunology
2 months ago
Development of a circadian immune system
#immunology
loading . . .
Development of a circadian immune system
Circadian rhythms are key regulators of immune functions. These endogenous oscillations help to maintain immune homeostasis, regulate responses to pathogens, and shape vaccine efficacy. Recent studies further indicate that they are of clinical relevance for cancer immunotherapies. While circadian immune rhythms are thus recognized to be important in adults, it is unknown at what developmental stage these rhythms begin to manifest. In this opinion article we review the development of circadian rhythms in the immune system in both rodents and humans, with a focus on their interactions during the perinatal period. Understanding their emergence in early life may help guide time-based clinical interventions for infants.
http://dlvr.it/TLtbwJ
0
2
1
reposted by
Silvana Novelli
STITCHES Medicine - the Best of Medical Research
3 months ago
Mindfulness and Tai Chi effectively enhance mood in cancer survivors, regardless of participants' intervention preferences. by Carlson LE, Jones JM (...) Speca M et 5 al. in J Clin Oncol
#MedSky
👉 get more
here
📖 read the article:
https://ascopubs.org/doi/10.1200/JCO-24-02540
0
10
1
reposted by
Silvana Novelli
Blood Journals' Portfolio
3 months ago
For patients who receive allo-HCT, socioeconomic barriers have a less pronounced impact on mortality.
buff.ly/8wTlcIF
#hemesky
#AML
0
2
1
Harmful but effective!
ashpublications.org/bloodneoplas...
loading . . .
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
Key PointsThe combination of rhIL-15 and mogamulizumab is associated with immunologic toxicity.NK cell activity increases within days of treatment and is a
https://ashpublications.org/bloodneoplasia/article/2/1/100054/525853/A-phase-1-study-of-interleukin-15-in-combination
4 months ago
0
0
0
reposted by
Silvana Novelli
NPR
4 months ago
In dire situations, stress can make us panic and impair our ability to make lifesaving decisions. Emergency response professionals share the tactics they use to stay cool and collected on the job.
loading . . .
COMIC: Don't panic! 6 strategies to keep you calm in a crisis
In dire situations, stress can make us panic and impair our ability to make lifesaving decisions. Emergency response professionals share the tactics they use to stay cool and collected on the job.
https://n.pr/43O43VV
11
457
125
Re-abriendo el melón de los péptidos derivados del timo y la respuesta inmune post tph.
www.sciencedirect.com/science/arti...
loading . . .
Thymic peptides in immune reconstitution and clinical outcome after allogeneic hematopoietic cell transplantation
Patients with hematologic malignancies or nonmalignant diseases may undergo allogeneic hematopoietic cell transplantation (HCT), which represents a po…
https://www.sciencedirect.com/science/article/pii/S2950328025000251
4 months ago
0
0
1
reposted by
Silvana Novelli
Alberto Mussetti
4 months ago
Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions url:
ashpublications.org/blood/articl...
0
1
1
reposted by
Silvana Novelli
Alberto Mussetti
4 months ago
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma | New England Journal of Medicine
www.nejm.org/doi/full/10....
loading . . .
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma | NEJM
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous...
https://www.nejm.org/doi/full/10.1056/NEJMoa2505133?query=RP
0
2
1
reposted by
Silvana Novelli
JAMA Oncology
4 months ago
Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare.
#ASCO25
@ascocancer.bsky.social
ja.ma/3FCoVHI
1
17
11
reposted by
Silvana Novelli
NEJM.org
4 months ago
Late breaking at
#ASCO25
: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial:
nej.md/4mh5RPL
@ascocancer.bsky.social
2
50
33
reposted by
Silvana Novelli
Sara R. Fagerlie, PhD, CHCP
4 months ago
Durable reponses with Allo-316 allogeneic CD70 CAR T-cell therapy in advanced clear cell RCC presented by Dr Srour at
#ASCO25
phase 1b TRAVERSE study
#RCCsm
#cansky
#oncsky
0
4
2
reposted by
Silvana Novelli
American Society of Hematology
4 months ago
In this episode of The Hematologist podcast, Dr. Michael Scott talks with Dr. Marc Michel about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Listen now:
ashpublications.org/...
#HemeSky
#MedSky
loading . . .
0
2
1
reposted by
Silvana Novelli
STITCHES Medicine - the Best of Medical Research
5 months ago
CNS border tissues facilitate immune communication, enhancing surveillance and protection without isolating the central nervous system. by Smyth LCD and Kipnis J in Nat Rev Immunol
#MedSky
👉 get more
here
📖 read the article:
loading . . .
Redefining CNS immune privilege - Nature Reviews Immunology
In this Perspective, Smyth and Kipnis reappraise the concept of immune privilege in the central nervous system. Although immune privilege was originally thought to involve isolation of the central nervous system from the peripheral immune system, the authors argue that it is instead a special immunological state that involves continuous neuroimmune dialogue.
https://www.nature.com/articles/s41577-025-01175-0
0
12
7
reposted by
Silvana Novelli
Alberto Mussetti
5 months ago
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine
www.nejm.org/doi/abs/10.1...
loading . . .
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...
https://www.nejm.org/doi/abs/10.1056/NEJMoa2408771
0
1
1
How can we better understand DLBCL? This new neural network, DLBclass, tackles this by assigning almost all cases to their C1-C5 genetic subtypes, unlocking valuable genetic information.
#translationalresearch
#hematology
#deeplearning
ashpublications.org/blood/articl...
loading . . .
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma
Key PointsWe developed a neural network–based probabilistic classifier, DLBclass, that assigns each DLBCL to its respective C1-C5 genetic subtype.DLBclass
https://ashpublications.org/blood/article/145/18/2041/534607/DLBclass-a-probabilistic-molecular-classifier-to
5 months ago
0
1
1
www.sciencedirect.com/science/arti...
loading . . .
The Role of Radiation Therapy for Palliation of Hematologic Malignancies
Palliative RT is an effective tool in management and treatment of patients with hematologic malignancies. Even relatively low doses of palliative RT c…
https://www.sciencedirect.com/science/article/abs/pii/S1053429624000857
5 months ago
0
2
0
reposted by
Silvana Novelli
Jeff Saucerman
6 months ago
Terrific paper by post-doc
@aclark.bsky.social
in
@plos.org
Comp Biol. This tutorial enables students and biologists to simulate biological networks with our tool Netflux, no programming required!
#sysbio
#cardiosky
🧪
add a skeleton here at some point
1
31
8
reposted by
Silvana Novelli
Alberto Mussetti
6 months ago
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
authors.elsevier.com/a/1ks1w5EIIg...
loading . . .
https://authors.elsevier.com/a/1ks1w5EIIgPexk
0
2
2
reposted by
Silvana Novelli
HematoRules
6 months ago
🚨 NEW
#ICOnic
PUBLICATION 🚨 Congratulations
@martape28.bsky.social
et al. For this paper! Now available online ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
www.nature.com/articles/s41...
loading . . .
Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC - Bone Marrow Transp...
Bone Marrow Transplantation - Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on...
https://www.nature.com/articles/s41409-025-02559-5
0
1
2
Relevant👇🏼👇🏼👇🏼👇🏼👇🏼
add a skeleton here at some point
6 months ago
0
0
0
reposted by
Silvana Novelli
Memorial Sloan Kettering Cancer Center
6 months ago
Research by MSK’s Dr. Ivan Maillard & collaborators at Univ. of Montréal have shed new light on the mechanisms governing an effective immune response to infections. The study focused on the early events in the response of immune cells called CD8+ T lymphocytes.
nouvelles.umontreal.ca/en/article/2...
0
10
3
Targeting CD3d is a feasible option after CD20 lost due to
#ofatumumab
in
#CLL
in a pts-derived xenograft model
ashpublications.org/blood/articl...
loading . . .
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Key PointsComplement-fixing CD20 mAbs deposit C3d on lymphoma cells; this neo-antigen can be selectively targeted to boost therapeutic efficacy.In B-cell l
https://ashpublications.org/blood/article-abstract/145/12/1309/534967/Potentiating-CD20-monoclonal-antibody-therapy-by?redirectedFrom=fulltext
6 months ago
0
3
2
reposted by
Silvana Novelli
Keisuke Ito
6 months ago
Thrilled to co-host Dr. Shu-Chi Allison Yeh from Rochester CMSR (
@urochester.bsky.social
) for the Einstein Stem Cell Institute seminar on intravital tracking and manipulation of the bone marrow niche at 3 PM, Monday, March 24th, with Dr. Steidl (
@steidluli.bsky.social
)!
@einsteinmededu.bsky.social
0
2
4
We still have some bullets but the escenario is dramatic
#mycosis
www.nature.com/articles/s41...
loading . . .
A polyene macrolide targeting phospholipids in the fungal cell membrane - Nature
Mandimycin, a polyene macrolide, exhibits strong antifungal activity and possesses a mode of action that is distinct from other compounds of this class.
https://www.nature.com/articles/s41586-025-08678-9
6 months ago
0
1
1
academic.oup.com/bjd/advance-...
loading . . .
Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas
We present ample evidence that the MHC-II chaperone CD74 is widely and robustly expressed in CTCL of all common subtypes including clinically challenging e
https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljaf001/8045421
6 months ago
0
0
0
reposted by
Silvana Novelli
Johanna Joyce
7 months ago
Researchers studying
#brain
#aging
took advantage of AI to analyze brain scans from nearly 39,000 people from the UK Biobank database 🧪🧠 They identified 64 genes linked to aging, and 13 potential drugs - including rapamycin - that may help slow brain decline..
www.nature.com/articles/d41...
loading . . .
How fast your brain ages is affected by these 64 genes
Scientists also identified anti-ageing drugs and experimental compounds that could target the genes to reverse decline.
https://www.nature.com/articles/d41586-025-00766-0
0
51
13
www.linkedin.com/posts/instit...
@sehhematologia.bsky.social
loading . . .
Catalan Institute of Oncology on LinkedIn: #mir #mir2025 #futursresidents #oncologia #hematologia #iconicpeople…
Futurs residents #MIR, us estem buscant! Has superat el MIR i ara arriba el moment decisiu: on vols formar-te com a especialista? Als centres Institut Català…
https://www.linkedin.com/posts/institut-catala-oncologia_mir-mir2025-futursresidents-activity-7302261553729298435-Cq1S?utm_source=share
7 months ago
0
0
0
reposted by
Silvana Novelli
Alberto Mussetti
7 months ago
www.sciencedirect.com/science/arti...
loading . . .
CAR T Outcomes in Patients with High-Grade B-Cell Lymphoma Not Otherwise Specified (HGBL-NOS): A CIBMTR Analysis
High-grade B-cell lymphoma not otherwise specified (HGBL-NOS) is a subtype of aggressive B-cell lymphoma with morphologic features intermediate betwee…
https://www.sciencedirect.com/science/article/abs/pii/S2666636725006220
0
2
1
The PEL-PS stratified patients into two groups: those with no negative factors had a median OS of 10.6 years, while those with 1-2 negative factors had a median OS of 0.8 years (p<0.0001). The PEL-PS effectively identifies prognosis and may guide treatment
onlinelibrary.wiley.com/doi/10.1002/...
loading . . .
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is tho...
https://onlinelibrary.wiley.com/doi/10.1002/ajh.27580
7 months ago
0
0
1
reposted by
Silvana Novelli
Eric Topol
7 months ago
At
@science.org
today, an important new way we can make major headway into immunologic and infectious diseases. Sequencing the lymphocyte B and T cell receptors and A.I. to accurately make the diagnosis!
www.science.org/doi/10.1126/science.adp2407
A seminal study by
@anshulkundaje.bsky.social
et al
4
295
66
¡Benvenuto!
@albertomussetti.bsky.social
#iconics
7 months ago
0
1
0
reposted by
Silvana Novelli
Xavier Trepat
8 months ago
New paper from the lab🎈. Introducing Micro Immune Response On-chip (MIRO), a device that replicates tumors and their microenvironment to better understand responses to immunotherapies (cyan=immune cells, red=cancer, green=CAFs).
www.nature.com/articles/s41...
@ibecbarcelona.eu
loading . . .
7
143
46
Things are getting better for AML! Amazing work!
add a skeleton here at some point
8 months ago
0
1
0
reposted by
Silvana Novelli
allie igwe
8 months ago
Checked on the article I wrote about Juneteenth in 2023… ”under review”
add a skeleton here at some point
6
160
90
reposted by
Silvana Novelli
Sharavan Vishaan V
8 months ago
Our new imaging protocol in
@natureportfolio.bsky.social
provides a unique way to study metabolic interactions in the tumour microenvironment.
#ImmunoSky
Read it here -
rdcu.be/d7WGO
doi.org/10.1038/s415...
Thanks to my collaborators:
@kreuzaler.bsky.social
@crick.ac.uk
@cancergrand.bsky.social
loading . . .
A multimodal imaging pipeline to decipher cell-specific metabolic functions and tissue microenvironment dynamics
Nature Protocols - Evaluating the metabolic organization of complex tissue microenvironments is useful for understanding cellular function within tissues. This protocol describes a multimodal...
https://rdcu.be/d7WGO
1
10
3
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study - The Lancet Oncology
www.thelancet.com/journals/lan...
loading . . .
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of...
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2824%2900598-9/fulltext
8 months ago
0
0
1
Load more
feeds!
log in
